CYP46A1 and Alzheimer disease: In addition, pharmacological and genetic induction of CYP46A1, an enzyme that catalyzes conversion of cholesterol to 24S-hydroxycholesterol, attenuates tau-associated pathologies in iPSC-derived AD neurons (van der Kant et al., 2019) and Tau22 mice expressing 1N4R human tau with G272V and P301S mutations (Burlot et al., 2015), respectively, whereas inhibition of CYP46A1 increases tau phosphorylation and Aβ-associated pathologies in APP23 mice expressing APPswe mutant (Djelti et al., 2015).